Experienced in Non-Alcoholic Fatty Liver Disease

Lu Y. Gan

509 Nanchang Road, 
Lanzhou, CN 
Experienced in Non-Alcoholic Fatty Liver Disease
509 Nanchang Road, 
Lanzhou, CN 
OverviewLocationsClinical Research

Overview

Lu Gan practices in Lanzhou, China. Ms. Gan is rated as an Experienced expert by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. Her top areas of expertise are Hyperthyroidism, Graves Disease, Asherman Syndrome, Trabeculectomy, and Intrauterine Device Insertion.

Her clinical research consists of co-authoring 631 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles in the study of Non-Alcoholic Fatty Liver Disease.

Gender
Female

Locations

509 Nanchang Road, Lanzhou, 730000, China
Other Locations
800 Dongchuan Rd, Shanghai, 200240, China
127 West Changle Road, Xi'an, 710032, China
28 Fuxing Road, Haidian, 100853, China
2Department Of Oncology, No.130, Dongan Road, Shanghai, 200032, China
Union Hospital, Wuhan, 430022, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 3

631 Total Publications

Discovery of Myrsinane Diterpenoids from Euphorbia prolifera as a New Type of Antiliver Fibrosis Agents That Inhibit the PI3K-AKT Signaling Pathway.
Discovery of Myrsinane Diterpenoids from Euphorbia prolifera as a New Type of Antiliver Fibrosis Agents That Inhibit the PI3K-AKT Signaling Pathway.
Journal: Journal of natural products
Published: January 20, 2026

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Gan's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 97 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile